Co-delivery of baicalein and doxorubicin by hyaluronic acid decorated nanostructured lipid carriers for breast cancer therapy.
- Resource Type
- Article
- Authors
- Liu, Qian; Li, Jia; Pu, Gaobin; Zhang, Fang; Liu, Hongyan; Zhang, Yongqing
- Source
- Drug Delivery. May2016, Vol. 23 Issue 4, p1364-1368. 5p.
- Subject
- *BREAST cancer treatment
*MULTIDRUG resistance
*DOXORUBICIN
*HYALURONIC acid
*LIPID nanotubes
- Language
- ISSN
- 1071-7544
Purpose: Combination anticancer therapy is promising to generate synergistic anticancer effects, to maximize the treatment effect and to overcome multi-drug resistance. Nanostructured lipid carriers (NLCs), composed of solid and liquid lipids, and surfactants are potentially good colloidal drug carriers. The aim of this study is to construct a hyaluronic acid (HA) decorated NLCs as nanocarriers for co-delivery baicalein (BCL) and doxorubicin (DOX). Methods: BCL- and DOX-loaded NLCs (BCL/DOX-NLCs) were prepared. HA ligands were used for the decoration of BCL/DOX-NLCs to form HA decorated BCL/DOX-NLCs (HA-BCL/DOX-NLCs). Thein vitrocytotoxicity studies of different formulations were evaluated on DOX drug-resistant MCF-7 breast cancer cell line (MCF-7/ADR cells).In vivoanti-tumor effects were observed on the murine bearing MCF-7/ADR cells model. Results: HA-BCL/DOX-NLCs showed highest cytotoxicity and synergistic effect of two drugs in tumor cellsin vitro. Thein vivostudy revealed the greatest anti-tumor activity than all the other formulations in the murine breast cancer model. Conclusions: HA decorated NLCs could be used as a novel carrier to co-delivery BCL and DOX for breast cancer therapy. HA-BCL/DOX-NLCs could be a promising targeted and combinational therapy nanomedicine. [ABSTRACT FROM AUTHOR]